Top

Archives of Gynecology and Obstetrics

Published in:

01-03-2019 | Maternal-Fetal Medicine

Dosing interval between mifepristone and misoprostol in second and third trimester termination

Authors: Natalia Prodan, Julia Breisch, Markus Hoopmann, Harald Abele, Philipp Wagner, Karl Oliver Kagan

Published in: Archives of Gynecology and Obstetrics | Issue 3/2019

Abstract

Objective

To compare several strategies for second trimester labor induction for termination of pregnancy (TOP) using misoprostol and mifepristone and to determine which one is more effective in accelerating the time to delivery.

Method

This was a retrospective study in which pregnancies that underwent second and third trimester TOP due to fetal anomalies between 2007 and 2017 were classified into a group that received misoprostol alone, a group that received mifepristone followed by misoprostol on the same day, one where misoprostol was given 1 day after mifepristone and one where the medications were administered 2 days apart. The primary outcome measure was the induction to delivery interval.

Results

481 pregnancies fulfilled the inclusion criteria. In 140 cases, mifepristone was not administered. 341 women received mifepristone prior to induction, which was administered on the day of induction in 85 cases, and 1 or 2 days prior to induction in 140 and 19 cases. Median time interval between first induction and delivery was 15.0 (IQR 10.0–24.1) h in case no mifepristone was given and 13.2 (9.7–18.2) h if mifepristone was given on the same day and 9.3 (6.6–14.9) and 10.5 (7.2–22.3) h, if mifepristone was given 1 or 2 days prior to induction. After 24 h, the proportion of terminated pregnancies in each of the four groups was 75.0, 83.5, 93.2 and 78.9%.

Conclusion

A 1 day interval between mifepristone and misoprostol is more effective in second and third trimester TOP compared to other strategies in terms of reducing the induction to abortion interval.

ESHRE Capri Workshop Group (2017) Induced abortion. Hum Reprod 32:1160–1169. https://doi.org/10.1093/humrep/dex071 CrossRef

Sedgh G, Bearak J, Singh S et al (2016) Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet 388:258–267. https://doi.org/10.1016/S0140-6736(16)30380-4 CrossRefPubMedPubMedCentral

Chae S, Desai S, Crowell M, Sedgh G (2017) Reasons why women have induced abortions: a synthesis of findings from 14 countries. Contraception 96:233–241. https://doi.org/10.1016/j.contraception.2017.06.014 CrossRefPubMedPubMedCentral

Wildschut H, Both MI, Medema S et al (2011) Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd005216.pub2 CrossRefPubMed

ACOG Practice Bulletin No. 135 (2013) Second-trimester abortion. Obstet Gynecol 121:1394–1406. https://doi.org/10.1097/01.aog.0000431056.79334.cc CrossRef

Lerma K, Shaw KA (2017) Update on second trimester medical abortion. Curr Opin Obstet Gynecol. https://doi.org/10.1097/gco.0000000000000409 CrossRefPubMed

Costescu D, Guilbert É (2018) No. 360-induced abortion: surgical abortion and second trimester medical methods. J Obstet Gynaecol Can 40:750–783. https://doi.org/10.1016/j.jogc.2017.12.010 CrossRefPubMed

World Health Organization (2014) Clinical practice handbook for safe abortion. http://apps.who.int/iris/bitstream/handle/10665/97415/9789241548717_eng.pdf;jsessionid=F3CA17048D0BF0E570DD6C8C1665AAC1?sequence=1. Accessed 01 Oct 2018

Hoopmann M, Hirneth J, Pauluschke-Fröhlich J et al (2014) Influence of mifepristone in induction time for terminations in the second and third trimester. Geburtsh Frauenheilk 74:350–354. https://doi.org/10.1055/s-0033-1360361 CrossRefPubMed

10.

Schreiber CA, Creinin MD, Atrio J et al (2018) Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med 378:2161–2170. https://doi.org/10.1056/NEJMoa1715726 CrossRefPubMedPubMedCentral

11.

Guest J, Chien P, Thomson M, Kosseim ML (2007) Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG Int J Obstet Gynaecol 114:207–215. https://doi.org/10.1111/j.1471-0528.2006.01179.x CrossRef

12.

Norman JE, Thong KJ, Baird DT (1991) Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 338:1233–1236CrossRefPubMed

13.

Mentula M, Suhonen S, Heikinheimo O (2011) One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy—a randomized trial. Hum Reprod 26:2690–2697. https://doi.org/10.1093/humrep/der218 CrossRefPubMed

14.

Wedisinghe L, Elsandabesee D (2010) Flexible mifepristone and misoprostol administration interval for first-trimester medical termination. Contraception 81:269–274. https://doi.org/10.1016/j.contraception.2009.09.007 CrossRefPubMed

15.

Schaff E (2006) Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception 74:42–44. https://doi.org/10.1016/j.contraception.2006.03.014 CrossRefPubMed

16.

Wagner N, Abele H, Hoopmann M et al (2011) Factors influencing the duration of late first and second-trimester termination of pregnancy with prostaglandin derivates. Eur J Obstet Gynecol Reprod Biol 155:75–78. https://doi.org/10.1016/j.ejogrb.2010.10.019 CrossRefPubMed

17.

Shaw KA, Topp NJ, Shaw JG, Blumenthal PD (2013) Mifepristone–misoprostol dosing interval and effect on induction abortion times. Obstet Gynecol 121:1335–1347. https://doi.org/10.1097/AOG.0b013e3182932f37 CrossRefPubMed

18.

Abbas DF, Blum J, Ngoc NTN et al (2016) Simultaneous administration compared with a 24-hour mifepristone–misoprostol interval in second-trimester abortion: a randomized controlled trial. Obstet Gynecol 128:1077–1083. https://doi.org/10.1097/AOG.0000000000001688 CrossRefPubMed

19.

World Health Organization (2017) The selection and use of essential medicines: report of the WHO Expert Committee, 2017. http://apps.who.int/iris/bitstream/handle/10665/259481/9789241210157-eng.pdf?. Accessed 01 Oct 2018

20.

Baev OR, Rumyantseva VP, Tysyachnyu OV et al (2017) Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 217:144–149. https://doi.org/10.1016/j.ejogrb.2017.08.038 CrossRefPubMed

21.

Hapangama D, Neilson JP (2009) Mifepristone for induction of labour. Cochrane Database Syst Rev 192:CD002865. https://doi.org/10.1002/14651858.cd002865.pub2 CrossRef

Title: Dosing interval between mifepristone and misoprostol in second and third trimester termination
Authors: Natalia Prodan
Julia Breisch
Markus Hoopmann
Harald Abele
Philipp Wagner
Karl Oliver Kagan
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2019
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-5017-9

At a glance: The STEP trials

Springer Medicine

Dosing interval between mifepristone and misoprostol in second and third trimester termination

Abstract

Objective

Method

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Urethral length and bladder neck behavior: can dynamic magnetic resonance imaging give the same results as introital ultrasound?

Laparoscopy versus open surgery for adnexal masses in pregnancy: a meta-analytic review

Demographic changes and effects on the mode of delivery: a retrospective analysis of a large birth registry containing 27,729 singleton deliveries in a level I center

Pelvic floor muscle training for prevention and treatment of urinary incontinence during pregnancy and after childbirth and its effect on urinary system and supportive structures assessed by objective measurement techniques

Rates of regression of cervical dysplasia between initial biopsy and excisional procedure in routine clinical practice

Prevalence of colonisation by group B streptococcus in pregnant patients in Taguatinga, Federal District, Brazil: a cross-sectional study